Atypical Presentation of Metformin- induced Lactic Acidosis in a Patient with Normal Renal Function: A Case Report
Abstract
Elevated lactate levels and high anion gap metabolic acidosis are hallmarks of Metformin-associated lactic acidosis, a rare but potentially fatal complication of Metformin therapy. Although the incidence of MALA is low, it carries a significantly high mortality rate, particularly in cases where diagnosis and treatment are delayed. Early recognition is therefore essential to improve clinical outcomes and reduce the risk of fatality.
MALA is most commonly associated with underlying conditions such as sepsis, hypoxia, or renal impairment, all of which can impair lactate clearance and exacerbate metabolic disturbances. However, it is important to note that MALA can also occur in the absence of these traditional risk factors, making diagnosis more challenging. This highlights the need for clinicians to maintain a high index of suspicion even in atypical presentations.
In this case, a patient with type 2 diabetes mellitus who had been receiving long-term metformin therapy presented with symptoms including nausea, vomiting, and altered mental status following a short episode of fever. Despite having normal renal function, laboratory investigations revealed severe metabolic acidosis, with a blood pH of less than 7.2 and markedly elevated lactate levels. These findings are consistent with a diagnosis of MALA, suggesting that metformin accumulation or altered metabolism may have contributed to the condition.
The probable cause of the patient’s metabolic disturbance was attributed to…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.